{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:16Z","timestamp":1793805916372,"version":"4.6.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.028","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:06:39Z","timestamp":1784372799000},"page":"535-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lutetium-177\u2013PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6112-116X","authenticated-orcid":false,"given":"Joseph","family":"McGrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudharshanan","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Sceats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bandyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2839","authenticated-orcid":false,"given":"KC","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.028_bib0001","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0002","unstructured":"U.S. Food and Drug Administration. FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration Accessed June 16, 2026."},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.028_bib0003","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10459","key":"10.1016\/j.urolonc.2026.06.028_bib0004","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"[177Lu]Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.028_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0006","first-page":"6","article-title":"Bone marrow dosimetry after [177Lu]Lu-PSMA-617 therapy using SPECT\/CT imaging: protocol simplification for clinical use","volume":"11","author":"Grob","year":"2024","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.028_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-023-00952-z","article-title":"Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation","volume":"13","author":"Peters","year":"2023","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.028_bib0008","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11864-025-01317-5","article-title":"PSMA-based therapies and novel therapies in advanced prostate cancer: the now and the future","volume":"26","author":"Ayzman","year":"2025","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.06.028_bib0009","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/ph18081215","article-title":"Targeted alpha therapy: exploring the clinical insights into [225Ac]Ac-PSMA and its relevance compared with [177Lu]Lu-PSMA in advanced prostate cancer management","volume":"18","author":"Jalloul","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.028_bib0010","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2967\/jnumed.124.269252","article-title":"Clinical trial protocol for LuCAB: a phase I-II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Kostos","year":"2025","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.028_bib0011","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/cancers17111820","article-title":"T-cell engager therapy in prostate cancer: molecular insights into a new frontier in immunotherapy","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.028_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.23736\/S1824-4785.24.03575-1","article-title":"New target therapies in prostate cancer: from radioligand therapy to PARP-inhibitors and immunotherapy","volume":"68","author":"Ceci","year":"2024","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"10276","key":"10.1016\/j.urolonc.2026.06.028_bib0013","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0014","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0015","article-title":"Lutetium-177\u2013PSMA radioligand therapy in metastatic castration-sensitive prostate cancer: a systematic review of efficacy, safety, and combination strategies","author":"Willis","year":"2025","journal-title":"PROSPERO"},{"issue":"36","key":"10.1016\/j.urolonc.2026.06.028_bib0016","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"[177Lu]Lu\u2013prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study","volume":"43","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.urolonc.2026.06.028_bib0017","doi-asserted-by":"crossref","first-page":"S1627","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 phase III trial of [177Lu]Lu-PSMA-617 combined with ADT plus ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.06.028_bib0018","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.028_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med."},{"issue":"7650","key":"10.1016\/j.urolonc.2026.06.028_bib0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"issue":"2 suppl","key":"10.1016\/j.urolonc.2026.06.028_bib0021","article-title":"A pilot study of stereotactic body radiotherapy and [177Lu]Lu-PSMA-617 for oligometastatic hormone-sensitive prostate cancer","volume":"117","author":"Imber","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.028_bib0022","first-page":"187","article-title":"Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: clinical experience","volume":"26","author":"Celen","year":"2023","journal-title":"Hell J Nucl Med."},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.028_bib0023","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"UpFrontPSMA Study Team. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomized, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.06.028_bib0024","first-page":"1068","article-title":"[177Lu]Lu-PSMA-617 consolidation therapy after docetaxel in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer: a randomized phase 2 trial (CONSOLIDATE)","volume":"66","author":"Satapathy","year":"2025","journal-title":"J Nucl Med."},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.028_bib0025","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1097\/RLU.0000000000004901","article-title":"Radioligand therapy with [177Lu]Lu-PSMA-I&T in patients with metastatic prostate cancer: oncological outcomes and toxicity profile","volume":"48","author":"Demirkol","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.028_bib0026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/cancers15010297","article-title":"PSMA-RLT in patients with metastatic hormone-sensitive prostate cancer: a retrospective study","volume":"15","author":"Banda","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"14","key":"10.1016\/j.urolonc.2026.06.028_bib0027","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study","volume":"27","author":"Priv\u00e9","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"suppl 2","key":"10.1016\/j.urolonc.2026.06.028_bib0028","first-page":"3083","article-title":"Early [177Lu]Lu PSMA radioligand therapy in metastatic non-castrate or castration-sensitive prostate cancer: long-term results","volume":"63","author":"Kulkarni","year":"2022","journal-title":"J Nucl Med."},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.028_bib0029","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00259-021-05471-4","article-title":"Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.028_bib0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MNM.0000000000001658","article-title":"Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry","volume":"44","author":"Uijen","year":"2023","journal-title":"Nucl Med Commun."},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.028_bib0031","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","article-title":"Lesion dosimetry for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration-sensitive prostate cancer","volume":"64","author":"Grkovski","year":"2023","journal-title":"J Nucl Med."},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.028_bib0032","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.23.01535","article-title":"Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer","volume":"42","author":"Halabi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.028_bib0033","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2026.06.028_bib0034","first-page":"S154","article-title":"Lutetium-177-PSMA-617 in oligo-metastatic hormone-sensitive prostate cancer (BULLSEYE). Presented at: annual Congress of the European Association of Nuclear Medicine (EANM); 2023; Vienna, Austria","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2026.06.028_bib0035","unstructured":"DUET Trial. A feasibility study of [177Lu]Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligometastatic hormone-sensitive prostate cancer after curative therapy (DUET). Onderzoek met Mensen (Dutch CCMO) Registry. Trial 56209. https:\/\/onderzoekmetmensen.nl\/en\/trial\/56209 Accessed August 2025."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0036","unstructured":"LADDER Trial. A phase II randomized study comparing [177Lu]Lu-PSMA-617 versus docetaxel in high-volume metastatic castration-sensitive prostate cancer (LADDER). ClinicalTrials.Gov identifier: NCT05939414. https:\/\/clinicaltrials.gov\/study\/NCT05939414 Accessed August 2025."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0037","unstructured":"STAMPEDE2 Trial. Systemic therapy in advancing or metastatic prostate cancer: evaluation of drug efficacy 2 (STAMPEDE2). ISRCTN Registry identifier: ISRCTN78818544. https:\/\/www.isrctn.com\/ISRCTN78818544 Accessed August 2025."},{"key":"10.1016\/j.urolonc.2026.06.028_bib0038","unstructured":"PEACE6 Trial. Standard of care \u00b1 [177Lu]Lu-PSMA-617 in de novo metastatic hormone-sensitive prostate cancer poor responders (PEACE-6). ClinicalTrials.Gov identifier: NCT06496581. https:\/\/clinicaltrials.gov\/study\/NCT06496581 Accessed August 2025."},{"issue":"8","key":"10.1016\/j.urolonc.2026.06.028_bib0039","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.028_bib0040","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.028_bib0041","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.028_bib0042","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.028_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.03.019","article-title":"Prostate-specific antigen response as a prognostic factor for overall survival in patients with prostate cancer treated with androgen receptor pathway inhibitors: a systematic review and meta-analysis","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.028_bib0044","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.028_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21873\/anticanres.15470","article-title":"The role of fast and deep PSA response in castration-sensitive prostate cancer","volume":"42","author":"Iacovelli","year":"2022","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.028_bib0046","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.028_bib0047","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.3390\/curroncol30040332","article-title":"Triplet therapy in metastatic castration-sensitive prostate cancer (mCSPC)\u2014a potential new standard of care","volume":"30","author":"Mittal","year":"2023","journal-title":"Curr Oncol."},{"issue":"10323","key":"10.1016\/j.urolonc.2026.06.028_bib0048","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.urolonc.2026.06.028_bib0049","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer (ARASENS)","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.028_bib0050","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1464-410X.2012.11774.x","article-title":"Androgen deprivation therapy: evidence-based management of side effects","volume":"111","author":"Ahmadi","year":"2013","journal-title":"BJU Int"},{"issue":"32","key":"10.1016\/j.urolonc.2026.06.028_bib0051","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.028_bib0052","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2967\/jnmt.122.264928","article-title":"Clinical trials of prostate-specific membrane antigen radiopharmaceutical therapy","volume":"51","author":"Jadvar","year":"2023","journal-title":"J Nucl Med Technol."},{"issue":"16","key":"10.1016\/j.urolonc.2026.06.028_bib0053","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.3390\/jcm13164585","article-title":"Investigating combination therapy: the role of lutetium-177 PSMA-617 radioligand therapy and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"13","author":"K\u0131n\u0131ko\u011flu","year":"2024","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.urolonc.2026.06.028_bib0054","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","article-title":"Deescalated [225Ac]Ac-PSMA-617 versus [177Lu]Lu\/[225Ac]Ac-PSMA-617 cocktail therapy: a single-center retrospective analysis of 233 patients","volume":"65","author":"Rathke","year":"2024","journal-title":"J Nucl Med."},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.028_bib0055","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14358","article-title":"[225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"55","author":"Garo","year":"2025","journal-title":"Eur J Clin Invest"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:26:28Z","timestamp":1793802388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005855"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lutetium-177\u2013PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}